|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.52 USD | -2.43% |
|
-1.96% | +78.09% |
| Mar. 05 | Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating | MT |
| Mar. 04 | US stocks close up on Iran diplomacy hopes; tech leads rebound | RE |
| Capitalization | 20.74B 17.88B 16.14B 15.49B 28.25B 1,906B 29.56B 191B 76.46B 914B 77.85B 76.19B 3,269B | P/E ratio 2026 * |
-7.57x | P/E ratio 2027 * | -11.5x |
|---|---|---|---|---|---|
| Enterprise value | 16.88B 14.55B 13.14B 12.6B 22.98B 1,551B 24.05B 155B 62.21B 744B 63.34B 61.99B 2,660B | EV / Sales 2026 * |
8.17x | EV / Sales 2027 * | 7.23x |
| Free-Float |
90.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Moderna, Inc.
| 1 day | -2.43% | ||
| 1 week | -1.96% | ||
| Current month | -1.96% | ||
| 1 month | +28.07% | ||
| 3 months | +89.60% | ||
| 6 months | +108.91% | ||
| Current year | +78.09% |
| 1 week | 48.09 |  | 59.55 |
| 1 month | 36.66 | | 59.55 |
| Current year | 29.81 | | 59.55 |
| 1 year | 22.28 | | 59.55 |
| 3 years | 22.28 | | 170.47 |
| 5 years | 22.28 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 2011-02-28 |
James Mock
DFI | Director of Finance/CFO | 49 | 2022-09-05 |
Stephen Hoge
PSD | President | 50 | 2024-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 66 | 2018-05-31 |
Noubar Afeyan
CHM | Chairman | 62 | 2012-01-31 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 2011-02-28 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.43% | -1.96% | +53.12% | -63.54% | 20.74B | |
| -0.66% | -2.79% | +8.79% | -2.63% | 77.98B | |
| -2.68% | -0.52% | +30.70% | +212.11% | 55.42B | |
| -0.18% | +64.40% | +64.40% | +64.40% | 51.24B | |
| -0.15% | -0.33% | -44.17% | -50.33% | 49.37B | |
| -1.71% | -3.62% | +25.45% | -31.59% | 27.13B | |
| -1.43% | -5.26% | +36.88% | +26.49% | 19.09B | |
| +6.18% | -2.12% | +106.44% | +96.23% | 18.48B | |
| -1.21% | -4.75% | +24.78% | +56.33% | 14.15B | |
| +0.27% | -8.47% | -4.48% | +912.21% | 13.43B | |
| Average | -0.40% | -3.74% | +30.19% | +121.97% | 34.7B | |
| Weighted average by Cap. | -0.69% | -3.19% | +23.80% | +73.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.07B 1.78B 1.61B 1.54B 2.81B 190B 2.95B 19.02B 7.62B 91.09B 7.76B 7.59B 326B | 2.53B 2.18B 1.97B 1.89B 3.45B 233B 3.61B 23.29B 9.33B 112B 9.5B 9.3B 399B |
| Net income | -2.74B -2.36B -2.13B -2.05B -3.73B -252B -3.9B -25.2B -10.09B -121B -10.28B -10.06B -432B | -1.82B -1.57B -1.41B -1.36B -2.47B -167B -2.59B -16.72B -6.7B -80.09B -6.82B -6.67B -286B |
| Net Debt | -3.86B -3.33B -3.01B -2.89B -5.26B -355B -5.51B -35.56B -14.25B -170B -14.51B -14.2B -609B | -2.44B -2.11B -1.9B -1.83B -3.33B -225B -3.48B -22.49B -9.01B -108B -9.17B -8.98B -385B |
Employees
4,700
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-03-06 | 52.52 $ | -2.43% | 12,432,558 |
| 26-03-05 | 53.83 $ | -6.87% | 13,953,534 |
| 26-03-04 | 57.80 $ | +15.99% | 23,103,642 |
| 26-03-03 | 49.83 $ | -5.71% | 9,258,801 |
| 26-03-02 | 52.84 $ | -1.35% | 9,424,727 |
Sell
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
52.52USD
Average target price
42.90USD
Spread / Average Target
-18.32%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
